



Algemene gegevens	
PPS-nummer	AF-18143
Titel	<b>No Guts No Glory</b> (previously Measurement of Gut Health)
Thema	Gezond & Veilig
Uitvoerende kennisinstelling(en)	TNO
Projectleider onderzoek (naam + emailadres)	Frank Schuren (frank.schuren@tno.nl)
Penvoerder (namens private	Matthijs Moerland (CHDR)
partijen)	Wilbert Sybesma (DSM)
Contactpersoon overheid (indien	Wijnie van Eck
relevant)	
Adres projectwebsite	https://topsectoragrifood.nl/project/af-18143- measurement-of-gut-health/
Startdatum	01-05-2019
Einddatum	30-04-2022

Goedkeuring penvoerder/consortium		
De jaarrapportage dient te worden besproken met de penvoerder/het consortium. De TKI's		
nemen graag kennis van eventuele opmerkingen over de jaarrapportage.		
De penvoerder heeft namens het	Υ goedgekeurd	
consortium de jaarrapportage		
Eventuele opmerkingen over de		
jaarrapportage:		

Inhoudelijke samenva	Inhoudelijke samenvatting van het project	
Probleemomschrijving	In this public private partnership TNO, DSM Nutritional Products and CHDR will investigate in healthy people (age 45+ years) the systemic health effects of modulating the gut microbiome using dietary fibers.	
	Disease prevention through improving human health is attracting more attention. The gut microbiome is an important new target in these approaches. However, even though the role of the microbiome in human health and disease is increasingly recognized, the specific relationships between gut microbiome and human health are largely unknown and there is an urgent need for new approaches to study this interaction, not only in lab mice but also in humans.	
Doelen van het project	Previously, TNO has developed two measurement solutions, one on the gut microbiome which is a platform called i-screen and one on measurement of health in form of resilience in healthy people (quantification of a person's phenotypic flexibility (personal response to a dietary challenge)).	
	<ul> <li>In the current project we will:</li> <li>Set up a clinical intervention study to investigate if it is possible to relate the effects of influencing the gut microbiome, by dietary fiber consumption, to health, which is quantified as a person's phenotypic flexibility.</li> <li>Report on the combination of in vitro (i-screen) and in vivo (from the clinical trial) gut microbiome data to investigate if only screening in vitro will provide clarity on effects.</li> </ul>	
	With this approach we would like to conclude on an important problem in the applied gut microbiome research in which many products show	

effects on gut microbiome, however effectiveness and contribution to general health are unclear.

The project is organized in five work packages (WP):

- WP2 Human intervention study including the design of the prebiotic fiber mix, the design and set-up of the clinical intervention, the final selection of biomarkers, writing the study protocol for METC approval, recruitment of subjects and execution of the clinical intervention study and sampling.
- WP3 Lab analyses including part a) on the analysis of biomarkers of the in vivo samples (blood, stool) and part b) the analysis of the in vitro stool samples (i-screen).
- WP4 Data analyses including data integration, visualization and statistics.
- WP5 Dissemination including scientific publications and presentations at conferences regarding the project and its outcomes.

Resultaten		
Beoogde resultaten	M1: Consortium agreement signed by all partners	
2019	D1: Final study protocol for the METC	
	M2: Approval of the protocol by the METC	
Behaalde resultaten 2019	The first milestone (M1) was the achieved in spring: the consortium agreement was signed by all partners and accordingly May 1 <sup>st</sup> 2019 is the official start date of the project. The name of the project was changed to "No Guts No Glory"	
	The main deliverable for 2019 was the protocol for to the Medical Ethical Committee (D1). This was sent to the METC November 4th, and early December we responded to their final question. Due to the Christmas Holidays official approval (M2) was given early 2020.	
	The final study design includes 4 Phenflex challenge tests and stool samples every 4 weeks. These frequent measurements will lead to a wealth of samples and data within a sound scientific design. A highlight is the fruitful collaboration with the partners so multiple win-win additions could be made to the study design. Additions include mental well-being, oral microbiome and biomarkers and experimental measures of vascular health.	
	Start study  N = 32  Prebiotics mix  Wash out  placebo	
	N = 32 Prebiotics mix	
	<ul> <li>▲ Feces collection (on site or via mail kit); i: i-screen on feces.</li> <li>● Challenge test on site (CHDR)</li> </ul>	
Beoogde resultaten 2020	Start human intervention study: first subject first visit M3a: Start in vitro analysis (i-screen) of the first samples Because of a faster execution of the activities planned for 2020 than originally anticipated, we expect the human samples to be ready (M3b) in Q4 2020 (instead of Q2 2021).	

<b>Opgeleverde producten in 2019</b> (geef de titels en/of omschrijvingen van de producten / deliverables of een link naar de producten op de projectwebsite of andere openbare websites)
Wetenschappelijke artikelen:
METC protocol for the study "A randomized, double-blind, placebo-controlled crossover study to assess the effect of 12-week fibre supplementation on mixed-meal challenge response in adults" (CHDR1901) to Stichting Beoordeling Ethiek Biomedisch Onderzoek (BEBO).
Externe rapporten:
NA NA
Artikelen in vakbladen:
NA
<u>Inleidingen/posters tijdens workshops, congressen en symposia:</u>
Presentation titled "Measuring gut health: Combining microbiome measurement and phenotypic flexibility to evaluate health effects of microbiome modulation" at the 13th International scientific conference on probiotics, prebiotics, gut microbiota and health (17-20th June 2019, Prague). https://www.probiotic-conference.net/ipc2019-conference-proceedings.htm
TV/ Radio / Social Media / Krant:
NA
Overig (Technieken, apparaten, methodes etc.):

NA